Torqur Ag

Akribes Biomedical Gmbh

Novartis Ag

Novartis Pharma Gmbh

Anton Stütz

Stefan Hirsch

Doriano Fabbro

Andreas Billich

Oskar Michael Kalb

Barbara Wolff-Winiski

Jean-Daniel Bonny

Petra Hillmann-Wüllner

Friedrich Karl Mayer

Petra Dörfler

Dieter Becker

Petra Hillmann-wüllner

Ernst Ulrich Kölle

Barbara Wolff-winiski

Nicole Schöfmann

Anthony Williams

Rainer Alles

The present invention relates to a compound of formula (I), wherein X, Xand Xare, independently of each other, N or CH; with the proviso that at least two of XXand Xare N; Y is N or CH; W is H or F; with the proviso that when W is F, then X, Xand Xare N; Rand Rare independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein Rand Rare independently of each other H, C-Calkyl optionally substituted with one or two OH, C-Cfluoroalkyl, C-Calkoxy, C-CalkoxyC-Calkyl, CN, or C(0)0-C-Calkyl; or Rand Rform together a bivalent residue —RR— selected from C-Calkylene optionally substituted with 1 to 4 F, —CH-0-CH—, —CH—NH—CH—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R; wherein Ris independently at each occurrence C-Calkyl optionally substituted with one or two OH, C-Cfluoroalkyl, C-CalkoxyC-Calkyl, C-Ccycloalkyl; or two Rsubstituents form together a bivalent residue —RR— selected from C-Calkylene optionally substituted with 1 to 4 F, —CH-0-CH— or -0-CHCH-0- with the proviso that at least one of Rand Ris a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis, a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars.

Treatment of skin disorders

The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.

Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for treating impaired skin wound healing

The present invention relates to an in vitro method for identifying a skin wound in an individual as being a non-healing skin wound or healing skin wound, in vitro methods for monitoring the healing of a skin wound in an individual, methods for screening for compounds suitable for modulating skin wound healing, as well as kits related thereto.

Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound

The present invention relates to a compound of formula (I), wherein X, Xand Xare, independently of each other, N or CH; with the proviso that at least two of XXand Xare N; Y is N or CH; W is H or F; with the proviso that when W is F, then Xi, Xand Xare N; Rand Rare independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein Rand Rare independently of each other H, C-Calkyl optionally substituted with one or two OH, C-Cfluoroalkyl, C-Calkoxy, C-CalkoxyC-Calkyl, CN, or C(O)O&#x2014;C-Calkyl; or Rand Rform together a bivalent residue &#x2014;RR&#x2014; selected from C-Calkylene optionally substituted with 1 to 4 F, &#x2014;CH&#x2014;O&#x2014;CH&#x2014;, &#x2014;CH&#x2014;NH&#x2014;CH&#x2014;, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R; wherein Ris independently at each occurrence C-Calkyl optionally substituted with one or two OH, C-Cfluoroalkyl, C-CalkoxyC-Calkyl, C-Ccycloalkyl; or two Rsubstituents form together a bivalent residue &#x2014;RR&#x2014; selected from C-Calkylene optionally substituted with 1 to 4 F, &#x2014;CH&#x2014;O&#x2014;CH&#x2014; or &#x2014;O&#x2014;CHCH&#x2014;O&#x2014;; with the proviso that at least one of Rand Ris a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis, a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars. 

Growing community of inventors

Altmünster, Austria

Anton Stütz